Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes management, not fertility treatment. However, many patients wonder whether Ozempic can increase fertility, particularly as weight loss achieved during treatment may restore ovulation in women with obesity-related reproductive dysfunction. Understanding the indirect relationship between Ozempic, metabolic health, and fertility is essential for safe prescribing and patient counselling. This article examines the evidence, explores how weight loss affects reproductive function, and outlines crucial safety considerations for women of childbearing potential taking Ozempic.

What Is Ozempic and How Does It Work?

Ozempic is the brand name for semaglutide, a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus. It belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the action of a naturally occurring hormone in the body that regulates blood sugar levels and appetite.

The medication is administered as a once-weekly subcutaneous injection, starting with a non-therapeutic initiation dose of 0.25 mg for 4 weeks, then titrating to maintenance doses of 0.5 mg, 1 mg, or 2 mg depending on individual response and tolerability. Ozempic works through several mechanisms: it stimulates insulin secretion from the pancreas when blood glucose levels are elevated, suppresses the release of glucagon (a hormone that raises blood sugar), slows gastric emptying to reduce post-meal glucose spikes, and acts on appetite centres in the brain to promote satiety and reduce food intake.

Whilst Ozempic is licensed specifically for type 2 diabetes management, patients using semaglutide typically experience substantial reductions in body weight alongside improvements in glycaemic control. Important safety considerations include risks of pancreatitis, gallbladder disease, and potential worsening of diabetic retinopathy with rapid HbA1c reduction. There is also an increased risk of hypoglycaemia when used with sulfonylureas or insulin. It is important to note that a higher-dose formulation of semaglutide, marketed as Wegovy, has been separately licensed for weight management in the UK, while Ozempic itself is not licensed for weight management.

The Link Between Ozempic, Weight Loss and Fertility

The relationship between Ozempic and fertility is primarily indirect, mediated through the medication's effects on body weight and metabolic health. Obesity is a well-established risk factor for reproductive dysfunction in both women and men, and weight loss achieved through any means can potentially improve fertility outcomes in individuals who are overweight or obese.

In women, excess body weight is strongly associated with polycystic ovary syndrome (PCOS), a common endocrine disorder characterised by irregular menstrual cycles, hyperandrogenism, and ovulatory dysfunction. Women with PCOS and obesity often experience insulin resistance, which contributes to hormonal imbalances that impair ovulation. Weight reduction of 5 to 10 per cent of total body weight has been associated with improvements in ovulatory cycles, hormonal profiles, and fertility in many women with PCOS, though individual responses vary. The substantial weight loss frequently observed with Ozempic treatment may therefore indirectly support improved reproductive function through these metabolic improvements.

In men, obesity has been associated with reduced testosterone levels, altered sperm parameters, and erectile dysfunction, though the evidence for fertility improvements with weight loss is less robust and more variable. The metabolic benefits of Ozempic extend beyond weight reduction alone: improvements in insulin sensitivity, reduction in systemic inflammation, and better glycaemic control all contribute to a more favourable hormonal environment that may support reproductive health.

It is crucial to understand that whilst weight loss achieved with Ozempic may improve fertility potential, this effect is a consequence of metabolic improvement rather than a direct pharmacological action of semaglutide on reproductive organs. Semaglutide is a GLP-1 receptor agonist (hormone analogue), not a sex hormone, and does not directly stimulate ovulation or sperm production.

Fertility Considerations When Taking Ozempic

Women of childbearing potential who are taking Ozempic must be aware of important safety considerations regarding pregnancy and contraception. The Summary of Product Characteristics for Ozempic, as approved by the MHRA, states that semaglutide should be discontinued at least two months before a planned pregnancy. This recommendation is based on the medication's long half-life and the limited data available regarding its safety during pregnancy.

Animal studies have suggested potential risks to foetal development, and whilst human data remain limited, the precautionary principle applies. Women taking Ozempic who are not planning pregnancy should use reliable contraception throughout treatment. While semaglutide does not reduce oral contraceptive efficacy, severe vomiting or diarrhoea (potential side effects) may affect pill absorption, so standard missed-pill guidance should be followed if these occur. Importantly, because Ozempic may restore ovulation in women with PCOS or obesity-related anovulation, there is a possibility of unplanned pregnancy occurring as fertility improves. Women who have experienced irregular or absent periods may suddenly begin ovulating regularly, increasing the chance of conception if contraception is not used consistently.

If pregnancy occurs whilst taking Ozempic, women should contact their GP or diabetes specialist promptly. The medication should be discontinued, and alternative management strategies for diabetes should be implemented. Insulin is generally considered the first-line option for managing diabetes during pregnancy, though metformin may also be appropriate in some cases, as outlined in NICE guidance (NG3). Semaglutide should not be used during breastfeeding.

Preconception care for women with diabetes should include aiming for an HbA1c below 48 mmol/mol where safely achievable, taking 5 mg of folic acid daily from preconception until 12 weeks of pregnancy, and receiving specialist preconception counselling. Men taking Ozempic do not face the same direct concerns regarding pregnancy, though they should be aware that weight loss and metabolic improvements may affect their fertility. Any couple actively trying to conceive should discuss their medications with their healthcare provider to ensure optimal preconception care.

Does Ozempic Directly Increase Fertility?

There is no robust clinical evidence that Ozempic directly increases fertility through a specific pharmacological action on reproductive organs or hormonal pathways. Semaglutide is not a fertility medication, and it has not been studied or licensed for the purpose of enhancing reproductive function. While GLP-1 receptors are primarily located in the pancreas, gastrointestinal tract, and brain regions involved in appetite regulation, their presence and clinical significance in reproductive tissues have not been definitively established in relation to fertility outcomes.

The apparent fertility-enhancing effects observed in some individuals taking Ozempic are best understood as secondary consequences of weight loss and metabolic improvement rather than direct drug effects. When overweight or obese individuals lose significant weight, their hormonal balance often shifts favourably: insulin sensitivity improves, androgen levels may normalise in women with PCOS, and inflammatory markers decrease. These metabolic changes can restore more regular ovulatory cycles and improve overall reproductive health, but these benefits would be expected with weight loss achieved through any method, whether medication-assisted, surgical, or lifestyle-based.

It is worth noting that some women have reported unexpected pregnancies whilst taking Ozempic, leading to anecdotal reports of the medication increasing fertility. However, these cases likely represent the restoration of fertility that was previously suppressed by obesity and metabolic dysfunction, rather than a direct fertility-enhancing effect of the drug itself. Women who have not been ovulating regularly due to weight-related factors may find that as they lose weight on Ozempic, their cycles normalise and conception becomes possible.

Patients with fertility concerns should be aware of UK referral pathways for fertility assessment, which typically recommend seeking specialist advice after 12 months of trying to conceive, or earlier (after 6 months) for women aged 36 or over, those with known fertility risk factors, or women with oligomenorrhoea/amenorrhoea. Those actively trying to conceive should be aware that semaglutide must be stopped at least two months before planned pregnancy. Conversely, those not planning pregnancy should ensure adequate contraception is in place, particularly if they have a history of irregular cycles that may normalise with treatment. For individuals with obesity-related infertility, a comprehensive approach addressing weight, metabolic health, and reproductive function under specialist guidance offers the best outcomes.

Frequently Asked Questions